DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 213 filers reported holding DENALI THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $642 | -26.6% | 31,102 | +4.8% | 0.00% | -33.3% |
Q2 2023 | $875 | +29.6% | 29,665 | +1.3% | 0.01% | +20.0% |
Q1 2023 | $675 | -7.2% | 29,287 | +12.0% | 0.01% | 0.0% |
Q4 2022 | $727 | -99.9% | 26,149 | -7.3% | 0.01% | -16.7% |
Q3 2022 | $866,000 | +112.3% | 28,221 | +103.3% | 0.01% | +100.0% |
Q2 2022 | $408,000 | -23.0% | 13,879 | -15.8% | 0.00% | 0.0% |
Q1 2022 | $530,000 | -23.6% | 16,488 | +5.9% | 0.00% | 0.0% |
Q4 2021 | $694,000 | +9.5% | 15,569 | +23.8% | 0.00% | 0.0% |
Q3 2021 | $634,000 | -21.2% | 12,573 | +22.6% | 0.00% | -25.0% |
Q2 2021 | $805,000 | +61.3% | 10,259 | +17.5% | 0.00% | +33.3% |
Q1 2021 | $499,000 | -17.4% | 8,733 | +21.0% | 0.00% | -25.0% |
Q4 2020 | $604,000 | – | 7,216 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |